Chargement en cours...
Towards personalized therapy for patients with glioblastoma
Combined therapy with temozolomide and radiotherapy is a standard treatment and improves the survival for patients with newly diagnosed glioblastoma. However, the prognosis remains poor, with a median survival time of 12–15 months. Currently, several clinical trials of dose-dense temozolomide regime...
Enregistré dans:
| Publié dans: | Expert Rev Anticancer Ther |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4297206/ https://ncbi.nlm.nih.gov/pubmed/22117160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.11.103 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|